SBIR Phase I: Enhancing the Efficacy of a Novel Cancer Drug through Combinatorial Chemistry

SBIR 第一阶段：通过组合化学增强新型抗癌药物的功效

• 批准号: 0419421
• 负责人: J. Paige Buchanan
• 金额: $ 9.99万
• 依托单位: Luna Innovations, Incorporated
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2004-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0419421&HistoricalAwards=false
• 关键词: SBIR; Phase; Enhancing; Efficacy; Novel

0419421StevensonThis Small Business Innovation Research Phase I project proposes to enhance the efficacy of a new anti-cancer drug, based on a novel lead molecule, through combinatorial chemistry. Preliminary data have shown that this drug, in higher doses, has the ability to kill cancerous cells while leaving non-cancerous cells unaffected.The commercial application of this project will be in the area of anti-cancer therapeutics for treatment of breast cancer.

0419421 StevensonThis Small Business Innovation Research Phase I project proposed to enhance efficacy of a new anti-cancer drug，based on a novel lead molecule，through combinational chemistry.初步数据表明，这种药物在较高剂量下具有杀死癌细胞而不影响非癌细胞的能力，该项目的商业应用将在治疗乳腺癌的抗癌疗法领域。